Heterologous Prime-Boost Vaccination Using an AS03B-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France

(2013) Yves Dauvilliers et al.   BRAIN

Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination

(2013) A. Szakacs et al.   NEUROLOGY

CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy

(2013) A. K. De la Herran-Arita et al.   Science Translational Medicine

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A

(2013) M.S. Heier et al.   SLEEP MEDICINE

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

(2013) E. Miller et al.   BMJ-British Medical Journal

An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

(2012) Paul Gillard et al.   Influenza and Other Respiratory Viruses

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Attack Rates Assessment of the 2009 Pandemic H1N1 Influenza A in Children and Their Contacts: A Systematic Review and Meta-Analysis

(2012) Aharona Glatman-Freedman et al.   PLoS One

The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

(2012) Leonoor Wijnans et al.   VACCINE

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china

(2011) Fang Han et al.   ANNALS OF NEUROLOGY

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months

(2011) George Risi et al.   VACCINE

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

(2010) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

(2008) Isabel Leroux-Roels et al.   PLoS One

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE